Accuray Inc
Research Accuray Inc (ARAY) on Bullrun: market cap USD 32.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARAY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 32.12M
- Financial periodQ1 2026
- RevenueUSD 104.85M
- Net income-USD 11.81M
- Free cash flow-USD 7.11M
- Gross margin24.1%
Valuation Snapshot
latest market cap is USD 32.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 458.51M | -USD 1.59M | -USD 1.41M | 32.1% | -0.02 | USD 57.42M | USD 136.52M | USD 81.17M |
| FY2024 | USD 446.55M | -USD 15.55M | -USD 15.51M | 32.0% | -0.16 | USD 68.57M | USD 172.16M | USD 45.08M |
| FY2023 | USD 447.61M | -USD 9.28M | USD 2.93M | 34.4% | -0.1 | USD 89.40M | USD 177.28M | USD 53.66M |
| FY2022 | USD 429.91M | -USD 5.35M | -USD 7.12M | 37.2% | -0.06 | USD 88.74M | USD 180.47M | USD 53.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 32.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 97.40M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 203.56M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 274.71M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 196.00M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 442.34M | n/a | n/a | n/a |
About Accuray Inc
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Accuray Inc's market cap?
Accuray Inc's market capitalization is USD 32.12M.
What does Accuray Inc do?
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.